ADVERTISEMENT ADVERTISEMENT Illumina Hit With Antitrust Suit Over Alleged Patent Fraud Law360 (January 11, 2021, 10:04 PM EST) -- Illumina stifled competition with fraudulently obtained patents and "baseless" infringement litigation, a rival company alleged Monday in a suit filed in California federal court, accusing the gene-sequencing behemoth of maintaining U.S. market dominance by defrauding the patent office and echoing the Federal Trade Commission's proclamation that Illumina is a "monopolist." Complete Genomics, a subsidiary of the Chinese genome-sequencing company BGI Group, claims that Illumina Inc. and Illumina Cambridge Ltd. violated the Sherman Antitrust Act and California's unfair competition laws by asserting at least three patents against it in federal court "in an unlawful, anticompetitive manner."